Skip to main content
Top
Published in: International Journal of Clinical Oncology 3/2016

01-06-2016 | Special Article

Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of ovarian cancer including primary peritoneal cancer and fallopian tube cancer

Authors: Shinichi Komiyama, Hidetaka Katabuchi, Mikio Mikami, Satoru Nagase, Aikou Okamoto, Kiyoshi Ito, Kenichiro Morishige, Nao Suzuki, Masanori Kaneuchi, Nobuo Yaegashi, Yasuhiro Udagawa, Hiroyuki Yoshikawa

Published in: International Journal of Clinical Oncology | Issue 3/2016

Login to get access

Abstract

The fourth edition of the Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer including primary peritoneal cancer and fallopian tube cancer was published in 2015. The guidelines contain seven chapters and six flow charts. The major changes in this new edition are as follows—(1) the format has been changed from reviews to clinical questions (CQ), and the guidelines for optimal clinical practice in Japan are now shown as 41 CQs and answers; (2) the ‘flow charts’ have been improved and placed near the beginning of the guidelines; (3) the ‘basic points’, including tumor staging, histological classification, surgical procedures, chemotherapy, and palliative care, are described before the chapter; (4) the FIGO surgical staging of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer was revised in 2014 and the guideline has been revised accordingly to take the updated version of this classification into account; (5) the procedures for examination and management of hereditary breast and ovarian cancer are described; (6) information on molecular targeting therapy has been added; (7) guidelines for the treatment of recurrent cancer based on tumor markers alone are described, as well as guidelines for providing hormone replacement therapy after treatment.
Appendix
Available only for authorised users
Literature
2.
go back to reference Heintz AP, Odicino F, Maisonneuve P et al (2006) Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95(Suppl 1):S161–S192CrossRefPubMed Heintz AP, Odicino F, Maisonneuve P et al (2006) Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 95(Suppl 1):S161–S192CrossRefPubMed
3.
go back to reference Gynecologic Cancer Committee (2012) Gynecologic cancer committee report in 2011. Acta Obstet Gynaecol Jpn 66:1024–1038 Gynecologic Cancer Committee (2012) Gynecologic cancer committee report in 2011. Acta Obstet Gynaecol Jpn 66:1024–1038
4.
go back to reference Ariyoshi H (2002) Guideline for correct use of antineoplastic agents (draft). General theory. Gan To Kagaku Ryoho 29:970–977PubMed Ariyoshi H (2002) Guideline for correct use of antineoplastic agents (draft). General theory. Gan To Kagaku Ryoho 29:970–977PubMed
5.
go back to reference Ochiai K, Okamoto A, Katsumata N (2002) Guidelines for proper use of antineoplastic agents. Gynecologic cancer. Gan To Kagaku Ryoho 29:1047–1054PubMed Ochiai K, Okamoto A, Katsumata N (2002) Guidelines for proper use of antineoplastic agents. Gynecologic cancer. Gan To Kagaku Ryoho 29:1047–1054PubMed
6.
go back to reference Fukui T, Yoshida M, Yamaguchi N (2007) Minds Guidance of practice guidelines 2007. Igakushoin, Tokyo Fukui T, Yoshida M, Yamaguchi N (2007) Minds Guidance of practice guidelines 2007. Igakushoin, Tokyo
7.
go back to reference Takeuchi H, Saeki T, Aiba K et al (2016) Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary. Int J Clin Oncol 21:1–12CrossRefPubMed Takeuchi H, Saeki T, Aiba K et al (2016) Japanese Society of Clinical Oncology clinical practice guidelines 2010 for antiemesis in oncology: executive summary. Int J Clin Oncol 21:1–12CrossRefPubMed
Metadata
Title
Japan Society of Gynecologic Oncology guidelines 2015 for the treatment of ovarian cancer including primary peritoneal cancer and fallopian tube cancer
Authors
Shinichi Komiyama
Hidetaka Katabuchi
Mikio Mikami
Satoru Nagase
Aikou Okamoto
Kiyoshi Ito
Kenichiro Morishige
Nao Suzuki
Masanori Kaneuchi
Nobuo Yaegashi
Yasuhiro Udagawa
Hiroyuki Yoshikawa
Publication date
01-06-2016
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 3/2016
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-016-0985-x

Other articles of this Issue 3/2016

International Journal of Clinical Oncology 3/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine